Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Equity Ratio (2016 - 2020)

Historic Equity Ratio for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to 0.9.

  • Larimar Therapeutics' Equity Ratio rose 3971.82% to 0.9 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.9, marking a year-over-year increase of 3971.82%. This contributed to the annual value of 0.13 for FY2019, which is 11741.96% down from last year.
  • Larimar Therapeutics' Equity Ratio amounted to 0.9 in Q3 2020, which was up 3971.82% from 0.9 recorded in Q2 2020.
  • In the past 5 years, Larimar Therapeutics' Equity Ratio registered a high of 0.93 during Q1 2017, and its lowest value of 0.13 during Q4 2019.
  • For the 5-year period, Larimar Therapeutics' Equity Ratio averaged around 0.76, with its median value being 0.79 (2018).
  • In the last 5 years, Larimar Therapeutics' Equity Ratio tumbled by 11741.96% in 2019 and then skyrocketed by 3971.82% in 2020.
  • Larimar Therapeutics' Equity Ratio (Quarter) stood at 0.92 in 2016, then dropped by 19.84% to 0.74 in 2017, then grew by 3.33% to 0.77 in 2018, then crashed by 117.42% to 0.13 in 2019, then surged by 775.01% to 0.9 in 2020.
  • Its Equity Ratio was 0.9 in Q3 2020, compared to 0.9 in Q2 2020 and 0.69 in Q1 2020.